HotSpot Therapeutics
PrivateLast Round
Series C
Nov 29, 2021
Total Funding Raised
$210M
Company Overview
HotSpot Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series C round in November 2021.
HotSpot Therapeutics is a biotechnology company that pioneers allosteric drug discovery by identifying and targeting natural regulatory hotspots on proteins to develop differentiated small molecule medicines for autoimmune diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HotSpot Therapeutics Comparables
Compare HotSpot Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Exo Therapeutics | 85% | |
| Allorion Therapeutics | 84% | |
| Nimbus Therapeutics | 83% |
For institutional investors. Book with your work email.
HotSpot Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 29, 2021 | ||||
| Series B | May 21, 2020 | ||||
| Series A | Jul 17, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HotSpot Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Brace Pharma Capital | Series B |
| EQT Life Sciences | Series C |
| B Capital Group | Series C |
| Pivotal bioVenture Partners | Series C |
| Tekla Capital Management | Series B, Series C |
| Nan Fung Group | Series C |
| Solasta Ventures | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Presented preclinical data at the 15th European Lupus Meeting.
- Mar 4, 2026
Launched interferon regulatory factor 5 (IRF5) program with preclinical data.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 28, 2026
HotSpot Therapeutics, Inc. plans to present a poster on preclinical data for HST-2011 at ACR Convergence 2026 in Orlando, Florida, from Nov 6th-11th '26.
- is_developingAug 18, 2026
HotSpot Therapeutics, Inc. is developing HST-2011, a potential once-daily oral therapy initially targeting lupus and other autoimmune conditions, as the program prepares to enter clinical testing.
- hiresAug 18, 2026
HotSpot Therapeutics, Inc. appoints Niti Goel, M.D., as Chief Medical Officer in Massachusetts on Aug 18th '26, as it prepares to advance its IRF5 inhibitor HST-2011 into clinical development for lupus and other autoimmune diseases.
- is_developingAug 18, 2026
As of Aug '26, HotSpot Therapeutics, Inc. is building a broad pipeline of novel allosteric therapies to treat autoimmune diseases.
For institutional investors. Book with your work email.
HotSpot Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HotSpot Therapeutics's valuation, stock price, and market status.
Is HotSpot Therapeutics a public or private company?
HotSpot Therapeutics is a private company.
What is the current stock price of HotSpot Therapeutics?
HotSpot Therapeutics is a private company, so its shares have no public market price. Caplight tracks HotSpot Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HotSpot Therapeutics worth (valuation)?
Valuation information for HotSpot Therapeutics is not publicly available.
Can I buy HotSpot Therapeutics stock?
HotSpot Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HotSpot Therapeutics's last funding round?
HotSpot Therapeutics's most recent funding round was Series C on November 29, 2021.
Who are the main investors in HotSpot Therapeutics?
Key investors in HotSpot Therapeutics include Pivotal bioVenture Partners, Nan Fung Group, Sofinnova Partners, Pivotal bioVenture Partners, Atlas Venture.
Will HotSpot Therapeutics IPO soon?
No public IPO plans have been announced for HotSpot Therapeutics.
How can I track HotSpot Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in HotSpot Therapeutics's shares on secondary markets.